CooperVision released new seven-year results from its crucial MiSight 1 day contact lens clinical trial on Tuesday. The firm, a global leader in myopia control and management for children, stated that 12 months after treatment discontinuation, mean axial elongation data show no sign of rebound impact, indicating that myopia control advantages are sustained. CooperVision presented the study’s findings during a special event here, as eye doctors gathered for the start of the American Academy of Optometry’s annual Academy meeting which runs from November 3 through the 6th 2021.
According to CooperVision, the multinational study is the world’s longest continuous running soft contact lens clinical trial for myopia control. CooperVision previously claimed that MiSight 1 day slowed myopia progression after numerous years of treatment. This was shown in a cohort that wore MiSight 1 day for the first six years of the trial, as well as the original control group, which was transferred to MiSight 1 day for three years.
MiSight 1 day contact lenses are specifically designed for myopia control and are FDA approved to slow the progression of myopia in children aged 8-12 at the initiation of treatment. In August, MiSight 1 day received approval from the Chinese National Medical Products Administration (NMPA) to become the first indicated product of any type that may slow the progression of axial length.